Merck scraps Covid-19 vaccine programs after they fail to measure up on efficacy in another major setback in the global fight
After turning up late to the vaccine development game in the global fight against Covid-19, Merck is now making a quick exit.
The pharma giant is reporting this morning that it’s decided to drop development of 2 vaccines — V590 and V591 — after taking a look at Phase I data that simply don’t measure up to either the natural immune response seen in people exposed to the virus or the vaccines already on or near the market.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,300+ biopharma pros reading Endpoints daily — and it's free.